Literature DB >> 6953222

The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia.

J R Priest, N K Ramsay, A J Bennett, W Krivit, J R Edson.   

Abstract

Hemostatic function was studied sequentially in 12 children receiving L-asparaginase, vincristine, and prednisone as remission induction chemotherapy for acute lymphoblastic leukemia. The three-week period of L-asparaginase therapy was characterized by progressive decreases in plasma antithrombin, plasminogen, and fibrinogen concentrations, and by progressive increases in plasma clotting times (prothrombin time, partial thromboplastin time, thrombin time). Platelet counts rose rapidly during the third and fourth weeks of therapy as bone marrow remission was achieved. Factor V levels increased steadily during a five-week period, perhaps related to vincristine or prednisone therapy. Recent reports of thrombosis and hemorrhage in children and adults receiving L-asparaginase may be explained by this complex set of abnormalities in coagulation and coagulation control.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6953222     DOI: 10.1016/s0022-3476(82)80536-2

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

1.  Coagulation Profile at Diagnosis in Patients with Acute Lymphoblastic Leukemia.

Authors:  Shivali Sehgal; Sunita Sharma; Jagdish Chandra; Anita Nangia
Journal:  Indian J Pediatr       Date:  2016-04-25       Impact factor: 1.967

2.  Neurosurgical management of L-asparaginase induced haemorrhagic stroke.

Authors:  Elisha Ogbodo; Chandrasekaran Kaliaperumal; Michael O'Sullivan
Journal:  BMJ Case Rep       Date:  2012-03-08

3.  Use of a synthetic protease inhibitor for the treatment of L-asparaginase-induced acute pancreatitis complicated by disseminated intravascular coagulation.

Authors:  M Murakawa; T Okamura; T Shibuya; M Harada; T Otsuka; Y Niho
Journal:  Ann Hematol       Date:  1992-05       Impact factor: 3.673

Review 4.  Plasminogen deficiency.

Authors:  Tiraje Celkan
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

5.  Coagulation factors and proteinase inhibitors in the plasma of children with acute lymphoblastic leukoses. Behaviour before and during treatment according to Protocol I of the Cooperative Leukaemia Study COALL-80.

Authors:  M Reitz; G Witzke; R Egbring; P Gutjahr
Journal:  Klin Wochenschr       Date:  1984-12-17

Review 6.  Mesenchymal stem cells as a double-edged sword in suppression or progression of solid tumor cells.

Authors:  Fatemeh Norozi; Ahmad Ahmadzadeh; Saeid Shahrabi; Tina Vosoughi; Najmaldin Saki
Journal:  Tumour Biol       Date:  2016-07-20

7.  A mouse model for glucocorticoid-induced osteonecrosis: effect of a steroid holiday.

Authors:  Lei Yang; Kelli Boyd; Sue C Kaste; Landry Kamdem Kamdem; Richard J Rahija; Mary V Relling
Journal:  J Orthop Res       Date:  2009-02       Impact factor: 3.494

8.  Metabolism of fibrinogen in children with acute lymphoblastic leukaemia.

Authors:  B Goldschmidt; R Koós
Journal:  Eur J Pediatr       Date:  1984-12       Impact factor: 3.183

9.  PTD-modified ATTEMPTS system for enhanced asparaginase therapy: a proof-of-concept investigation.

Authors:  Young Min Kwon; Yong Tao Li; Jun F Liang; Yoon Jeong Park; Li-Chien Chang; Victor C Yang
Journal:  J Control Release       Date:  2008-06-26       Impact factor: 9.776

10.  First-line treatment of acute lymphoblastic leukemia with pegasparaginase.

Authors:  Riccardo Masetti; Andrea Pession
Journal:  Biologics       Date:  2009-07-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.